Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
J Orthop Traumatol ; 18(4): 359-364, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28664414

RESUMO

BACKGROUND: Congenital muscular torticollis (CMT) is seen in childhood and presents within months after birth. The etiology remains unknown; however, medical textbooks suggest trauma at birth as a main reason. The aim of this study was to systematically describe obstetric and perinatal outcomes in a population of children with a confirmed congenital muscular torticollis diagnosis. MATERIALS AND METHODS: Children with a validated diagnosis of congenital muscular torticollis born at Aarhus University Hospital from 2000 to 2014 were included in the study. Information on perinatal, intrapartum and neonatal characteristics were obtained from databases and from medical records, and systematically described. RESULTS: In this study, there were no differences in birth characteristics in children with left- and right-sided torticollis, between boys and girls or between the conservatively treated and the children who needed surgery. Most of the children with congenital muscular torticollis in this study were delivered at term without signs of birth complications or trauma. None experienced moderate or severe asphyxia. CONCLUSIONS: The results of the present study suggests that complicated birth or birth trauma may not be the main cause of congenital muscular torticollis and point towards intrauterine and prenatal reasons for its development. LEVEL OF EVIDENCE ACCORDING TO OCEBM LEVELS OF EVIDENCE WORKING GROUP: 3.


Assuntos
Complicações na Gravidez , Torcicolo/congênito , Traumatismos do Nascimento/complicações , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Resultado da Gravidez , Estudos Retrospectivos , Fatores de Risco , Torcicolo/etiologia
2.
Scand J Clin Lab Invest ; 63(4): 247-58, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12940632

RESUMO

A genetic contribution to the development of osteoporosis is well documented. Although the association between the common allelic variation of apolipoprotein E (APOE), fracture risk, bone loss and bone mineral density (BMD) has been examined in several studies, the results of these investigations are contradictory. The aim of this study was to examine the association between polymorphisms of APOE, BMD of the lower forearm, quantitative ultrasound of the calcaneus and osteoporotic fractures in a population of postmenopausal women with hip or lower forearm fractures admitted to a department of orthopaedic surgery and age-matched controls from the population register. The APOE genotypes of 327 women were studied: 73 with lower forearm fractures, 43 with hip fractures and 211 age-matched controls. The participants were not receiving antiosteoporotic treatment. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) was used to detect the APOE genotypes. Quantitative ultrasound was measured at the calcaneus. Bone mineral density (BMD) of the lower forearm was measured with dual-energy X-ray absorptiometry. The distributions of genotype frequencies in this study were: E2/E2: 0.3%; E2/E3: 16.5%; E2/E4: 2.5%; E3/E3: 54.7%; E3/E4: 24.2%; E4/E4: 1.8%. All subpopulations were in Hardy-Weinburg equilibrium. There was no association between bone mass parameters and the APOE allele groups. Logistic regression analysis did not show any association between fractures and APOE allele groups. In conclusion, this study showed no association between bone mass parameters (BMD, speed of sound (SOS), broadband ultrasound attenuation (BUA)), hip or lower forearm fracture and APOE genotypes in a population of postmenopausal women and age-matched controls.


Assuntos
Apolipoproteínas E/genética , Calcâneo/diagnóstico por imagem , Antebraço/diagnóstico por imagem , Fraturas Ósseas/diagnóstico , Fraturas Ósseas/genética , Osteoporose Pós-Menopausa/diagnóstico , Osteoporose Pós-Menopausa/genética , Idoso , Alelos , Densidade Óssea , Feminino , Traumatismos do Antebraço/diagnóstico por imagem , Traumatismos do Antebraço/genética , Fraturas Ósseas/diagnóstico por imagem , Genótipo , Fraturas do Quadril/diagnóstico por imagem , Fraturas do Quadril/genética , Humanos , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/diagnóstico por imagem , Polimorfismo Genético , Radiografia , Ultrassonografia
3.
Ugeskr Laeger ; 163(32): 4195-7, 2001 Aug 06.
Artigo em Dinamarquês | MEDLINE | ID: mdl-11510237

RESUMO

INTRODUCTION: The aim of the study was to describe the clinical, radiological, and functional results of intramedullary nailing of deformities in the lower extremities of children with osteogenesis imperfecta after the use of multiple osteotomies and non-telescoping rods (rush pins). MATERIAL AND METHODS: Eight children with osteogenesis imperfecta, who consecutively underwent surgery during 1991-1994, were entered in the study. RESULTS: Sixteen operations were performed on eight children: 12 on the femur and four on the tibia. Like others, we found a high complication rate, 50%. Radiological correction of angular deformities was good. The functional outcome was satisfactory and the patients were satisfied. CONCLUSION: Correction and stabilisation of deformities in the lower extremities in children with osteogenesis imperfecta with the use of non-telescoping rods is an acceptable method of decreasing fractures and allowing most formerly non-ambulatory children to walk. Furthermore, the cosmetics were improved.


Assuntos
Pinos Ortopédicos , Fêmur/cirurgia , Osteogênese Imperfeita/cirurgia , Osteotomia/métodos , Tíbia/cirurgia , Adolescente , Criança , Pré-Escolar , Feminino , Fêmur/diagnóstico por imagem , Seguimentos , Marcha , Humanos , Masculino , Osteogênese Imperfeita/diagnóstico por imagem , Osteogênese Imperfeita/fisiopatologia , Satisfação do Paciente , Radiografia , Tíbia/diagnóstico por imagem
4.
Mol Cell Endocrinol ; 172(1-2): 203-11, 2001 Feb 14.
Artigo em Inglês | MEDLINE | ID: mdl-11165054

RESUMO

Three breast carcinoma cell lines were tested for 17beta-estradiol (E(2)) mediated regulation of vasoactive intestinal polypeptide receptor type-1 (VPAC(1)) expression. In all three, E(2) was found to down-regulate the mRNA level. We studied T47D cells in more details and found a 25 and 70% decrease in the VPAC(1) mRNA level upon 7 and 48 h of E(2) treatment, respectively. The number of vasoactive intestinal polypeptide (VIP) binding sites was reduced 66% upon treatment with E(2) for 72 h. After cycloheximide pretreatment, the E(2) mediated mRNA reduction was attenuated from 50% to 25% after 24 h suggesting the effect to be at least partly independent of protein synthesis. Experiments with the transcriptional inhibitor actinomycin D showed that E(2) did not influence the VPAC(1) mRNA half-life while nuclear run-on experiments indicated that E(2) decreased the VPAC(1) transcription rate. Two antiestrogens: ICI 182780 (ICI) and 4-hydroxy-tamoxifen (4-OHT) mediated a concentration dependent inhibition of E(2)'s effect on the mRNA level. Transient transfection with reporter-gene constructs containing various portions of the VPAC(1) 5'-flanking sequence revealed the most proximal 100 bp to be essential for the basal transcriptional activity. However, E(2) did not influence the expression of the reporter gene using up to 3250 bp of the VPAC(1) 5'-flariking region.


Assuntos
Neoplasias da Mama/metabolismo , Regulação para Baixo/efeitos dos fármacos , Estradiol/farmacologia , Receptores de Peptídeo Intestinal Vasoativo/genética , Regiões 5' não Traduzidas/genética , Ligação Competitiva/efeitos dos fármacos , Antagonistas de Estrogênios/farmacologia , Humanos , Regiões Promotoras Genéticas/genética , RNA Mensageiro/fisiologia , Receptores de Peptídeo Intestinal Vasoativo/metabolismo , Receptores Tipo I de Polipeptídeo Intestinal Vasoativo , Células Tumorais Cultivadas/efeitos dos fármacos
5.
Orthopedics ; 23(3): 223-6, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10741366

RESUMO

Between 1986 and 1991, a total of 18 patients (11 men and 7 women) with osteochondritis dissecans of the knee were treated with periosteal transplantation. Median patient age was 19 years (range: 16-45 years). Eight patients were reoperated up to 8 years postoperatively, due to reduced range of motion, synovitis, or formation of an exostosis in the transplanted area. Of 14 patients who were available for follow-up after 8 years (range: 5-10), 2 were completely pain free. Six patients had reduced range of motion, knee instability, or quadriceps muscle atrophy. The number of reoperations and the presence of continued knee pain in most patients does not justify the extensive procedure of periosteal transplantation.


Assuntos
Transplante Ósseo , Joelho/cirurgia , Osteocondrite Dissecante/cirurgia , Adolescente , Adulto , Fenômenos Biomecânicos , Feminino , Humanos , Joelho/patologia , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Reoperação , Estudos Retrospectivos
6.
Ann N Y Acad Sci ; 921: 33-6, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11193846

RESUMO

The breast carcinoma cell line T47D was tested for 17 beta-estradiol (E2) mediated regulation of vasoactive intestinal polypeptide receptor type-1 (VPAC1) expression. E2 was found to downregulate the mRNA level. The number of VIP binding sites was reduced 66% on treatment with E2 for 72 h. Experiments with cycloheximide suggested that the effect was independent (at least partly so) of protein synthesis. Experiments with the transcriptional inhibitor, actinomycin D, showed that E2 did not influence the VPAC1 mRNA halflife. Both of two antiestrogens, ICI 182,780 and 4-hydroxy-tamoxifen, mediated a concentration dependent inhibition of the effect of E2 on the mRNA level. Transient transfection with reporter-gene constructs containing various portions of the VPAC1 5'-flanking sequence revealed the most proximal 100 bp to be essential for the basal transcriptional activity. However, E2 did not influence the expression of the reporter gene using up to 3,250 bp of the VPAC1 5'-flanking region.


Assuntos
Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Receptores de Peptídeo Intestinal Vasoativo/genética , Mama/metabolismo , Dactinomicina/farmacologia , Regulação para Baixo/efeitos dos fármacos , Estradiol/farmacologia , Moduladores de Receptor Estrogênico/farmacologia , Feminino , Humanos , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , RNA Neoplásico/genética , RNA Neoplásico/metabolismo , Receptores Tipo I de Polipeptídeo Intestinal Vasoativo , Transcrição Gênica/efeitos dos fármacos , Transfecção , Células Tumorais Cultivadas , Peptídeo Intestinal Vasoativo/metabolismo
8.
Biomacromolecules ; 1(4): 622-6, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11710191

RESUMO

The structure of a single thread of Nephila edulis silk has been studied by in situ X-ray diffraction from a living spider. A systematic increase of orientational order with increasing silking speed up to 40 mm s-1 was observed. Within a few mm from the spinnerets exit, crystalline domains with a beta-poly(L-alanine) structure were observed. The data also suggest an increase in crystalline fraction in the immediate vicinity of the spigot exit.


Assuntos
Proteínas de Insetos/efeitos da radiação , Aranhas/fisiologia , Algoritmos , Animais , Cristalografia por Raios X , Microscopia Eletrônica de Varredura , Seda , Síncrotrons , Resistência à Tração , Raios X
9.
J Gen Virol ; 80 ( Pt 12): 3241-3250, 1999 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10567657

RESUMO

Transcription of the human papillomavirus type 16 (HPV-16) genome is controlled by several promoters; the P(97) promoter is considered to be the main one. An additional promoter has been identified within the E7 ORF as well as an antisense promoter just upstream of the L2 ORF. The significance of these promoters for early and late gene expression and their activity related to cell differentiation is not known in detail. Identification of two new, previously undescribed transcription start sites at nt 542 just upstream of the E7 ORF and at nt 611 within the E7 ORF is reported. The promoter responsible for the start site at nt 542 (P(542)) was active in SiHa, HeLa and C33A cells. Very low promoter activity was found upstream of the nt 611 start site. The E7 protein has previously been shown to be synthesized from a polycistronic mRNA encoding both the E6 and E7 proteins under the control of the P(97) promoter. The data reported in the present paper suggest that promoter P(542) may control synthesis of the E7 oncoprotein from a monocistronic mRNA.


Assuntos
Proteínas Oncogênicas Virais/genética , Papillomaviridae/genética , Regiões Promotoras Genéticas , Transcrição Gênica , Sequência de Bases , Linhagem Celular , Clonagem Molecular/métodos , DNA Complementar/genética , Elementos Facilitadores Genéticos , Regulação Viral da Expressão Gênica , Células HeLa , Humanos , Queratinócitos , Dados de Sequência Molecular , Fases de Leitura Aberta , Proteínas E7 de Papillomavirus , Mutação Puntual
10.
Cancer ; 86(6): 1080-6, 1999 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-10491537

RESUMO

BACKGROUND: 6-Mercaptopurine (6MP) has been regarded as nonleukemogenic, even though the cytotoxicity of 6MP depends on the incorporation of 6-thioguanine nucleotides (6TGN) into DNA. In hematopoietic cells this pathway competes with S-methylation catalyzed by thiopurine methyltransferase (TPMT). However, methylated 6MP metabolites inhibit purine de novo synthesis and thus may enhance incorporation of 6TGN into DNA. Approximately 10% of white individuals have low TPMT activity as a result of polymorphisms in the TPMT gene. The authors attempted to test the hypothesis that the degree of DNA damage during 6MP therapy might reflect variations in 6MP metabolism and pharmacokinetics. METHODS: The authors measured TPMT activity as well as erythrocyte levels of 6TGN (E-6TGN) and methylated 6MP metabolites (E-MeMP) during 6MP therapy in 439 children with acute lymphoblastic leukemia, 5 of whom later developed secondary myelodysplasia or acute myeloid leukemia (sMDS/AML). RESULTS: The patients who developed sMDS/AML had significantly lower TPMT activity compared with the remaining patients (P = 0.03). The 55 patients with TPMT activity <14 U/mL red blood cells (RBC) (antimode of the bimodal distribution) had a 5-year risk of sMDS/AML of 9 +/- 6% versus 1 +/- 1% for the remaining patients (P = 0.002). Cox regression analysis identified TPMT activity and E-MeMP level as the strongest predictors of risk for sMDS/AML (global P value = 0.02). Patients with low TPMT activity and high E-MeMP levels had the highest risk. All 5 patients with sMDS/AML had E-6TGN and/or E-MeMP levels > the 90% percentiles or had TPMT activity < 14 U/mL RBC. CONCLUSIONS: These data demonstrate an increased leukemogenic risk when 6MP is administered with other cytotoxic agents in patients with low TPMT activity, and indicate that not only high 6TGN levels but also high levels of methylated metabolites may lead to DNA damage.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Células da Medula Óssea/efeitos dos fármacos , Mercaptopurina/efeitos adversos , Síndromes Mielodisplásicas/induzido quimicamente , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adolescente , Células da Medula Óssea/metabolismo , Criança , Pré-Escolar , Dano ao DNA , Nucleotídeos de Guanina/metabolismo , Humanos , Imunofenotipagem , Lactente , Mercaptopurina/administração & dosagem , Metiltransferases/genética , Metiltransferases/metabolismo , Risco , Tionucleotídeos/metabolismo
11.
Tidsskr Nor Laegeforen ; 119(4): 499-503, 1999 Feb 10.
Artigo em Norueguês | MEDLINE | ID: mdl-10081372

RESUMO

From 1975 to 1980, 153 Norwegian children were diagnosed with acute lymphocytic leukaemia. In 1995, all 98 survivors were studied and compared to matched family controls. 132 children were treated with the national protocol. Of these, 93 (70.5%) were survivors at the time of the study. The remaining five survivors were treated with different treatment schemes. The national protocol included methotrexate infusions combined with intrathecal methotrexate as prophylactics against neuroleukaemia, instead of the irradiation. Neither doxorubicin nor cyclophosphamide were included. In this study, a questionnaire was used that covered demographic data, quality of life, and medical information the response rates were 96% (94 persons) for survivors and 92% (90 persons) for family controls. Information was also obtained for the remaining four survivors. No significant differences were found between survivors and controls with regard to quality of life and demographics, with one exception, Somatisation on the GHQ-28. Hospital records of all patients were checked for possible late effects. One case of serious sequela (hemiparesis during therapy) was found, probably related to methotrexate therapy. Seven other serious, possible sequelae were recorded, but probably not related to methotrexate. There were no cases of secondary malignant neoplasm.


Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Metotrexato/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras , Qualidade de Vida , Adolescente , Adulto , Antimetabólitos Antineoplásicos/efeitos adversos , Criança , Feminino , Seguimentos , Humanos , Masculino , Metotrexato/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/psicologia , Programas Médicos Regionais , Fatores Socioeconômicos , Inquéritos e Questionários , Sobreviventes/psicologia , Resultado do Tratamento
12.
Obstet Gynecol ; 93(5 Pt 2): 807-9, 1999 May.
Artigo em Inglês | MEDLINE | ID: mdl-10912401

RESUMO

BACKGROUND: Women with endometrial carcinoma are being treated with laparoscopic surgery, but the risk of port-site recurrences remains undefined. CASE: A 58-year-old woman underwent laparoscopically assisted vaginal hysterectomy, bilateral salpingo-oophorectomy, and laparoscopic lymphadenectomy for endometrial cancer. Final surgical stage was IA, with grade 2 histology. Twenty-one months later, she developed a 5-cm recurrent tumor mass at a lateral laparoscopic port site. The mass was resected, and a restaging laparotomy performed, without evidence of other metastases. Radiation therapy was administered to the involved anterior abdominal wall. Two and one half years later, there is no evidence of recurrence. CONCLUSION: An isolated laparoscopic port-site recurrence might be attributable to the initial laparoscopic management of an otherwise good-prognosis endometrial carcinoma.


Assuntos
Neoplasias Abdominais/secundário , Adenocarcinoma/secundário , Neoplasias do Endométrio/patologia , Histerectomia Vaginal/efeitos adversos , Laparoscopia/efeitos adversos , Inoculação de Neoplasia , Adenocarcinoma/cirurgia , Neoplasias do Endométrio/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia
13.
Cancer Res ; 58(21): 4845-50, 1998 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-9809989

RESUMO

Four breast carcinoma cell lines (T47D, ZR-75-1, MDA-MB-231, and MCF-7) were tested for regulation of the expression of vasoactive intestinal polypeptide receptor type-1 (VIP-R1). In all four cell lines, retinoic acid (RA) treatment caused a fast and marked decrease in VIP-R1 mRNA level as examined by Northern blots. Cycloheximide pretreatment attenuated the effect from 3- to 2-fold, indicating that existing proteins can mediate the decreasing effect of RA, but to attain the maximal effect new protein synthesis might be needed. Transcriptional inhibition with Actinomyocin D showed that RA did not influence the VIP-R1 mRNA half-life, indicating that the decreasing effect of RA on the mRNA level is due to transcriptional inhibition. In agreement with the observations on mRNA level, we found that the VIP receptor number was reduced 3-fold from 88 to 32 fmol/10(6) cells in T47D cells and from 222 to 73 fmol/10(6) cells in MDA-MB-231 cells upon RA treatment for 72 h. The promoter and 5'-flanking region of the VIP-R1 gene were cloned from a human placental cosmid library, and 2.5 kb were sequenced to search for regulatory elements. Our results, therefore, imply that the regulation of VIP-R1 gene expression by RA could have a role in human mammary tumor biology.


Assuntos
Neoplasias da Mama/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Receptores de Peptídeo Intestinal Vasoativo/efeitos dos fármacos , Tretinoína/farmacologia , Sequência de Bases , Sítios de Ligação , Neoplasias da Mama/tratamento farmacológico , Clonagem Molecular , Regulação para Baixo , Feminino , Humanos , Dados de Sequência Molecular , RNA Mensageiro/análise , Receptores de Peptídeo Intestinal Vasoativo/genética , Receptores Tipo I de Polipeptídeo Intestinal Vasoativo , Células Tumorais Cultivadas
14.
Acta Paediatr ; 87(6): 638-43, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9686656

RESUMO

In the present population-based study, we compared the clinical data of testicular relapses with and without concurrent bone marrow relapse and clinical data of the relapses in other locations among boys with acute lymphoblastic leukaemia (ALL), in order to study the possible evidence of early sequestration and local regulation of leukaemic lymphoblast in the testis of humans. The results suggest that the pathogenesis of isolated testicular relapse (T) and testicular relapse with a concurrent bone marrow relapse (T + BM) is likely to be similar. Isolated and non-isolated testicular relapses appeared late after the achievement of remission (T 34 +/- 16 months, T + BM 32 +/- 15 months) in ALL compared to relapses in other locations (CNS 23 +/- 11 months, BM 25 +/- 19 months). The better prognosis after testicular relapses (estimated second event free survival probability, 2-EFS: T 0.63, T + BM 0.32) compared to bone marrow relapse (2-EFS: BM 0.13) further suggests that testicular relapse with a concurrent bone marrow relapse possibly originates from the isolated testicular relapse, and that the isolated testicular relapse is a separate entity and not a manifestation of systemic recurrence. Higher frequencies of isolated and non-isolated testicular relapses (T 9%, T + BM 5%) were observed among boys with onset of ALL in early puberty (10-12 y) compared to those among younger (T 4%, T + BM 2%) and older (T 0%, T + BM 0%) boys. The late occurrence, the possible association with hormonal maturation and the good prognosis after testicular relapses suggest a possible local regulation of the residual leukaemic lymphoblast in human testis.


Assuntos
Neoplasias da Medula Óssea/patologia , Infiltração Leucêmica/patologia , Recidiva Local de Neoplasia/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Neoplasias Testiculares/patologia , Adolescente , Idade de Início , Biópsia por Agulha , Neoplasias da Medula Óssea/epidemiologia , Criança , Pré-Escolar , Intervalo Livre de Doença , Seguimentos , Humanos , Lactente , Infiltração Leucêmica/diagnóstico , Infiltração Leucêmica/epidemiologia , Masculino , Recidiva Local de Neoplasia/epidemiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Prevalência , Prognóstico , Medição de Risco
15.
Mol Endocrinol ; 12(8): 1140-9, 1998 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9717840

RESUMO

GH exerts adipogenic activity in several preadipocyte cell lines, whereas in primary rat preadipocytes, GH has an antiadipogenic activity. To better understand the molecular mechanism involved in adipocyte differentiation, the expression of adipocyte-specific genes was analyzed in differentiating preadipocytes in response to GH. We found that the expression of both adipocyte determination and differentiation factor 1 (ADD1) and peroxisome proliferator activated receptor gamma(PPARgamma) was induced in preadipocytes during differentiation. In the presence of GH, which markedly inhibited triglyceride accumulation, no reduction in the expression level of ADD1 was observed in response to GH, whereas there was a 50% reduction in the expression of PPARgamma. The DNA binding activity of the PPARgamma/retinoid X receptor-alpha(RXRalpha) to the ARE7 element from the aP2 gene was also reduced by approximately 50% in response to GH. GH inhibited the expression of late markers of adipocyte differentiation, fatty acid synthase, aP2, and hormone-sensitive lipase by 70-80%. The antiadipogenic effect of GH was not affected by the mitogen-activated protein (MAP) kinase/ extracellular-regulated protein (ERK) kinase inhibitor PD 98059, indicating that the mitogen-activated protein kinase pathway was not involved in GH inhibition of preadipocyte differentiation. The expression of preadipocyte factor-1/fetal antigen 1 was decreased during differentiation, and GH treatment prevented this down-regulation of Pref1/FA1. A possible role for Pref-1/FA1 in mediating the antiadipogenic effect of GH was indicated by the observation that FA1 inhibited differentiation as effectively as GH. These data suggest that GH exerts its inhibitory activity in adipocyte differentiation at a step after the induction of ADD1 but before the induction of genes required for terminal differentiation.


Assuntos
Adipócitos/efeitos dos fármacos , Proteínas Estimuladoras de Ligação a CCAAT , Regulação da Expressão Gênica/efeitos dos fármacos , Hormônio do Crescimento/farmacologia , Proteínas de Neoplasias , Proteínas do Tecido Nervoso , Animais , Proteínas de Ligação ao Cálcio , Proteínas Quinases Dependentes de Cálcio-Calmodulina/efeitos dos fármacos , Proteínas Quinases Dependentes de Cálcio-Calmodulina/metabolismo , Proteínas de Transporte/genética , Proteínas de Transporte/metabolismo , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas , Proteínas de Ligação a DNA/efeitos dos fármacos , Proteínas de Ligação a DNA/genética , Proteína 7 de Ligação a Ácidos Graxos , Proteínas de Ligação a Ácido Graxo , Flavonoides/farmacologia , Glicoproteínas/genética , Glicoproteínas/farmacologia , Insulina/farmacologia , Peptídeos e Proteínas de Sinalização Intercelular , Masculino , Proteínas de Membrana/efeitos dos fármacos , Proteínas de Membrana/genética , Proteína P2 de Mielina/genética , Proteína P2 de Mielina/metabolismo , Proteínas Nucleares/efeitos dos fármacos , Proteínas Nucleares/genética , Dibutirato de 12,13-Forbol/farmacologia , Ratos , Ratos Sprague-Dawley , Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos , Receptores Citoplasmáticos e Nucleares/genética , Proteínas Repressoras/efeitos dos fármacos , Proteínas Repressoras/genética , Proteína de Ligação a Elemento Regulador de Esterol 1 , Fatores de Transcrição/efeitos dos fármacos , Fatores de Transcrição/genética
16.
Brain Res ; 791(1-2): 290-4, 1998 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-9593948

RESUMO

The modulatory effect of PACAP27 on NMDA receptor channel activity in cultured chick cortical neurons was investigated using the outside-out recording mode of the patch clamp technique. Channel opening frequency elicited by 20 microM NMDA, or 20 microM NMDA plus 1 microM glycine, was potentiated in the presence of 100 nM PACAP27 and inhibited with 1000 nM PACAP27. These effects were reversible on washout and reduced when glycine concentration was increased to 10 microM, but were not affected by the PACAP antagonist PACAP6-27 (1 microM) or the GTP inhibitor GDP-beta-S (100 microM). It is suggested that PACAP27 may exert its modulatory action on NMDA receptor channel activity through the glycine site(s).


Assuntos
Córtex Cerebral/efeitos dos fármacos , Canais Iônicos/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Neuropeptídeos/farmacologia , Neurotransmissores/farmacologia , Receptores de N-Metil-D-Aspartato/efeitos dos fármacos , Animais , Células Cultivadas , Córtex Cerebral/citologia , Córtex Cerebral/metabolismo , Embrião de Galinha , Neurônios/metabolismo , Técnicas de Patch-Clamp , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Receptores de N-Metil-D-Aspartato/metabolismo
17.
Pediatr Hematol Oncol ; 14(6): 513-24, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9383804

RESUMO

In a follow-up matched control study the 93 (70.5%) survivors of 132 children treated with a national protocol for acute lymphoblastic leukemia (ALL) and 5 survivors of the other 21 cases of ALL in childhood diagnosed in the same period were evaluated. Thus it was also a population-based study. The national treatment protocol was used in the period 1975-1980. Methotrexate (MTX) infusions combined with intrathecal MTX were used as prophylaxis against neuroleukemia instead of irradiation. Neither doxorubicin (Adriamycin) nor cyclophosphamide was used in the protocol. A questionnaire covering demographic data, number of offspring, learning problems, level of athletic performance, education, and work status as well as medical information was used. Forms were received from 94 (96%) of the 98 adult surviving cases and corresponding controls in the family. Interviews were performed in the remaining four cases (4%). There were no statistical differences between the two groups with respect to physical and mental health and quality of life. Hospital records of all patients were also checked for possible late effects. There was no definite case of secondary malignant neoplasm; however, there was one case of prolactinoma and only one case of serious sequelae (hemiparesis during therapy), probably due to intrathecal and intravenous MTX.


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/psicologia , Qualidade de Vida , Taxa de Sobrevida
18.
J Neurophysiol ; 78(4): 2231-4, 1997 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9325391

RESUMO

The outside-out recording mode of the patch-clamp technique was used to study modulatory effects of pituitary adenylate cyclase-activating polypeptide (PACAP38) on N-methyl--aspartate (NMDA) receptor activity in cultured chick cortical neurons. Biphasic concentration-dependent effects of PACAP38 on channel opening frequency induced by NMDA (20 microM) and glycine (1 microM) were found, with low concentrations (0.5-2 nM) of PACAP38 increasing activity and higher concentrations (10-1,000 nM) causing inhibition. These effects were reversible, reduced with higher concentrations of glycine (2-10 microM) but not by 200 microM NMDA, and inhibited by 10 microM 7-chlorokynurenic acid. In addition, 1 microM PACAP6-38 (a PACAP antagonist) inhibited channel activity due to 20 microM NMDA and 1 microM glycine by 66%, and this inhibition was reduced to 13% in the additional presence of 2 nM PACAP38. These observations suggest that PACAP38 has a direct modulatory effect on the NMDA receptor that is independent of intracellular second messengers and probably mediated through the glycine coagonist site(s).


Assuntos
Córtex Cerebral/efeitos dos fármacos , Neuropeptídeos/farmacologia , Neurotransmissores/farmacologia , Receptores de N-Metil-D-Aspartato/efeitos dos fármacos , Animais , Células Cultivadas , Embrião de Galinha , Glicina/farmacologia , Neurônios/efeitos dos fármacos , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase
20.
Acta Oncol ; 35(1): 57-61, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8619941

RESUMO

In a randomized double-blind cross-over trial, sustained-release metoclopramide (S) plus methylprednisolone (M) was compared with placebo (P) plus methylprednisolone as antiemetic prophylaxis during two cycles of non-cisplatin chemotherapy. S was administered as 60 mg every 12 h commencing on the evening before chemotherapy up to total of 300 mg metoclopramide in 2.5 days. Evaluation of nausea and vomiting was done by self-assessment schemes and visual analog scales. Fifty patients were included and 36 fulfilled both cycles. Mild nausea and vomiting were experienced by 81% and 83% in the S + M and P + M groups, respectively, while 42% and 39% showed complete control of nausea and vomiting during the first day of treatment. Moderate-dose S did not add to the antiemetic efficacy of M in non-cisplatin chemotherapeutic regimens.


Assuntos
Antieméticos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Metilprednisolona/uso terapêutico , Metoclopramida/uso terapêutico , Adulto , Antieméticos/sangue , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama Masculina/tratamento farmacológico , Quimioprevenção , Cisplatino/administração & dosagem , Estudos Cross-Over , Preparações de Ação Retardada , Método Duplo-Cego , Quimioterapia Combinada , Tolerância a Medicamentos , Feminino , Humanos , Masculino , Metoclopramida/sangue , Náusea/prevenção & controle , Neoplasias Ovarianas/tratamento farmacológico , Autoavaliação (Psicologia) , Vômito/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA